Clinical Trial Update: Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the combination of romidepsin and carfilzomib in relapsed/refractory peripheral T cell lymphoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Carfilzomib (carfilzomib)
• Romidepsin (romidepsin)

Snippet

Sponsor: University of Birmingham | Conditions: Peripheral T Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED